Otherindependent cross-checkabstract checked★ key study I-CHM-123 standard review
How much does chemotherapy add to cancer survival overall?
The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies.
Overview
Morgan G et al.. Clin Oncol (R Coll Radiol) 2004 · PMID 15630849 · DOI 10.1016/j.clon.2004.06.007
Across all adult cancer patients, the authors estimated that about 2% are alive at 5 years because of chemotherapy alone.
Does the study support the specific claim? Partly · Methodological quality: low
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Estimate population-level contribution of chemotherapy
- How was the study done?
Modelling from trials and registries
- How many people, animals or samples were studied?
22 cancer types
- What was actually found?
About 2.3% of all patients
- How large was the observed effect?
2.1-2.3%
- What do the results mean in everyday life?
Chemotherapy is not the main reason most people survive cancer (surgery and early detection are)
- What are the study's limitations?
Denominator includes patients who never needed chemotherapy
- What does it say about Elawady's specific claim?
Gives partial support to scepticism, but not to refusing indicated treatment
- Do the results apply to Germany and Europe?
Low
- What can explicitly not be concluded from this study?
Cannot show chemotherapy is useless for a given patient
Scientific in-depth review
1. Full reference
- Authors
- Morgan G et al.
- Journal
- Clin Oncol (R Coll Radiol)
- Year
- 2004
- Identifier
- PMID 15630849 DOI 10.1016/j.clon.2004.06.007
- Verification
- verified – PubMed efetch 2026-10-26 (PublicationType and CommentsCorrections checked); Crossref 2026-10-26
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Not stated in abstract.
2. Research question
What share of all adult cancer patients survive 5 years because of curative or adjuvant cytotoxic chemotherapy?
3. Study design and population
- Study design
- Other – Literature-based modelling study combining RCT survival gains with registry incidence
- Population
All newly diagnosed adult cancer patients (22 malignancies)
- Country
Australia, USA
- Period
Registry data 1998; RCTs to about 2004
- Sample size
22 malignancies
- Inclusion and exclusion criteria
RCTs reporting 5-year survival benefit attributable solely to cytotoxic chemotherapy
4. Methods and endpoints
- Exposure / intervention
Curative/adjuvant cytotoxic chemotherapy
- Comparator
No chemotherapy (in source RCTs)
- Endpoints
5-year survival gain attributable to chemotherapy, as % of all patients
- Statistical methods
Sum of (incidence x proportion benefiting x survival gain) / total incidence
5. Actual results
- Results
Overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival: 2.3% (Australia) and 2.1% (USA).
- Absolute risks
2.3% of all adult cancer patients
- Authors' conclusion
Cytotoxic chemotherapy makes only a minor contribution to cancer survival; rigorous evaluation of cost-effectiveness and quality of life is needed.
6. Strengths
- Transparent population-level arithmetic
7. Weaknesses
- Denominator includes all cancer patients, most of whom are not chemotherapy candidates
- Counts only 5-year survival gains attributable solely to chemotherapy (excludes palliation, life extension <5 years, combined-modality gains)
- 1998 data; a published comment exists (Clin Oncol 2005;17(4):294; not read)
8. Risk of bias
- Orienting tool
- none applicable
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- high
- Rationale
Modelling with selective inputs; not a measure of benefit for patients in whom chemotherapy is indicated.
9. Assessment of the statistical interpretation
The 2.3% is a population-weighted average, not an effect size for treated patients; e.g., in CONKO-001 the gain is 10 points of 5-year survival among patients actually treated.
10. Relevance to the specific claim
The strongest published source on the 'chemotherapy helps little' side. It supports a narrow point: across all adult cancers, cytotoxic chemotherapy alone explains a small part of overall survival. It does not show that chemotherapy is useless or harmful for patients in whom it is recommended.
11. Independent contrary findings
EBCTCG meta-analyses (I-CHM-01, I-CHM-101), CONKO-001 (I-CHM-120), NSCLC MAC (I-CHM-103).
12. Transferability to Germany and Europe
Old data; newer treatments not included.
13. Overall methodological judgement
Methodologically weak for the purpose it is often quoted for.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | low |
| Risk of bias | high |
| Precision of results | not applicable |
| Directness | indirect |
| Reproducibility | not replicated |
| Consistency with the overall evidence | inconsistent |
| Regional transferability | low |
| Adequacy of the interpretation (by the archive) | not applicable |
14. Open questions
Updated estimate with current regimens.
15. Linked fact checks
- The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits. – Studies with mixed or unclear results
- Oncology only buys time: 'survival rates' are meaningless, patients die during treatment, and early diagnosis only makes you 'die early'. – Studies with mixed or unclear results